AndreaBozzo/ceres-open-data-index huggingface dataset:
NNDSS - TABLE 1LL. Vibriosis, Confirmed to Vibriosis, Probable

NNDSS - TABLE 1LL. Vibriosis, Confirmed to Vibriosis, Probable – 2020.  In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.

Note: 
This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. 

Footnotes:
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published.
NC: Not calculated — There is insufficient data available to support the calculation of this statistic.
Cum: Cumulative year-to-date counts.
Max: Maximum — Maximum case count during the previous 52 weeks.
* Case counts for reporting years 2019 and 2020 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf.
†Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).
Compound 526480: Carteolol, PFB-TMS

Chemical compound data from PubChem database. IUPAC Name: N-tert-butyl-2,2,3,3,4,4,4-heptafluoro-N-[3-[(2-oxo-3,4-dihydro-1H-quinolin-5-yl)oxy]-2-trimethylsilyloxypropyl]butanamide. Molecular Formula: C23H31F7N2O4Si. Molecular Weight: 560.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E401827-T1: [Translated] DEVICE FOR COLLECTING, ANALYZING AND TRANSPORTING A SALIVA SAMPLE

An oral fluid collection and transfer device comprises a collection device (10) and a test cartridge (100). The collection device includes a frame or chassis (14), and an absorbing pad (12) for absorbing oral fluid and which is secured around part of the frame with part of the frame protruding from the pad. A collapsible cover (16) covers the absorbing means and has apertures (68) forthe ingress of oral fluid into contact with the absorbing pad. Acap (18) covers the part of the frame protruding from the absorbing pad. The cap and the cover latch together to surround the frame and the absorbing pad. The device also includes a fluid adequacy indicator (20) in the form of an electrical circuit with an LED (66) which is completed when the absorbing means has absorbed a predetermined volume of oral fluid. The test cartridge (100) has a collection chamber (110) to allow insertion of the collection device into the test cartridge. A test strip (150) is used to for test the oral fluid for the presence of analytes. The collection device (10) is located at a fixed location relative to the test cartridge (100) within the collection chamber(110), in which location the absorbing pad (12) undergoes a controlled degree of compression, thereby transferring a predetermined volume of oral fluid from the absorbing pad to the test strip. A transportation vial may also be provided for the secure transportation of a sample of oral fluid to a laboratory for test verification. After initial testing, the collection device (10) is inserted into a transportation vial (180) wherein the remaining oral fluid contained within the collection device (10) is transferred to a sample vial (190) containing a preservative substance to prevent degradation of the sample during transportation. The collection device (10) and transportation vial (180) are repackaged and sealed with a tamper proof seal before being returned to a laboratory for confirmation or further tests. <IMAGE> <IMAGE>
Role of epidermal growth factor receptor activation in regulating mucin synthesis

Healthy individuals have few goblet cells in their airways, but in patients with hypersecretory diseases goblet-cell upregulation results in mucus hypersecretion, airway plugging, and death. Multiple stimuli produce hypersecretion via epidermal growth factor receptor (EGFR) expression and activation, causing goblet-cell metaplasia from Clara cells by a process of cell differentiation. These cells are also believed to be the cells of origin of non-small-cell lung cancer, but this occurs via cell multiplication. The mechanisms that determine which pathway is chosen are critical but largely unknown. Although no effective therapy exists for hypersecretion at present, the EGFR cascade suggests methods for effective therapeutic intervention.
Louisiana AFCARS Assessment Review, 2013

This webpage includes the documentation from Louisiana's Adoption and Foster Care Analysis and Reporting System (AFCARS) assessment review for fiscal year 2013:

AFCARS Assessment Review Letter

AFCARS Assessment Review Report

Tab A - Detailed Findings

Findings Instructions

Section I

AFCARS Assessment Review Findings - General Requirement

Section II

AFCARS Assessment Review Findings - Foster Care and Adoption Elements

Section III

AFCARS Case File Summary Report

AFCARS Assessment Review Case File Findings - Foster Care and Adoption Elements

Tab B - AFCARS Improvement Plan

Improvement Plan Instructions

Section I

AFCARS Assessment Review Improvement Plan - General Requirements

Section II

AFCARS Assessment Review Improvement Plan - Foster Care and Adoption Elements

Metadata-only record linking to the original dataset. Open original dataset below.
NYTD Reviewer Qualifications

On behalf of the Children’s Bureau, JBS International, Inc.'s Child Welfare Compliance Reviews Team (CWCRT) recruits young people to support the Children’s Bureau in administering the federal National Youth in Transition Database (NYTD) Reviews.

The minimum and preferred (additional) qualifications to become a NYTD Reviewer are summarized below. If a young person meets the minimum qualifications and is interested in NYTD data collection, analysis, and/or data-driven work, we welcome their inquiry or application.

If you believe you meet the minimum qualifications and are interested in learning more, please email CWCRT at cw-mail@jbsinternational.com for a NYTD Reviewer application packet.

Metadata-only record linking to the original dataset. Open original dataset below.
Localities for 2023

2023: The CY 2023 Medicare Physician Fee Schedule has been updated by the annual PFS Final Rule for various new policies and for new and existing CPT/HCPCS codes for this latest calendar year. This includes implementing all recent legislation as directed by Congress and enacted by the Consolidated Appropriations Act (CAA) of 2023, signed into law of December 29, 2022, of which becomes effective starting January 1, 2023, with PFS conversion factor of $33.8872. The Geographic Practice Cost Index (GPCI) work floor of 1.0 continues to be extended through to the end of CY 2023.
Diagnostic strategies for C-reactive protein

Background
          Serum C-reactive protein (CRP) has been identified in prospective epidemiological research as an independent risk marker for cardiovascular disease. In this paper, short-term biological variation of CRP is documented and a strategy to test the reliability of a single CRP sample is proposed.
        
        
          Methods
          Data were obtained from three groups of healthy volunteers: men, no oral contraceptives (OC-)using women and OC-using women. Blood samples were obtained 3 times in men and twice in women during a workweek.
        
        
          Results and discussion
          CRP values were highest in the OC-using women, followed by the men, and lowest in the no OC-using women. Averaged over the three groups the within-subject coefficients of variation (CVi) was 49.24% for CRP, and 29.90% for lnCRP. Using the repeated measures, individual samples were identified that reflected a 'suspicious' unreliable high value, i.e. a value that was more than 2 standard deviations higher than the lowest value obtained from the same subject. In an a posteriori analysis, three strategies to identify these suspicious high CRP values were then tested. In terms of maximizing detection of suspicious values and minimizing unnecessary resampling, best results were obtained for the most pragmatic criterion of using an absolute level, stratified for gender, and OC-use, to decide whether a second sample should be obtained.
        
        
          Conclusion
          A single high CRP value must be followed by re-sampling when it is above 1.75 mg/l for men, above 1.00 mg/l for no OC-using women, and above 2.00 mg/l for OC-using women.
Compound 529750: Chrysanthenyl isovalerate

Chemical compound data from PubChem database. IUPAC Name: (2,7,7-trimethyl-6-bicyclo[3.1.1]hept-2-enyl) 3-methylbutanoate. Molecular Formula: C15H24O2. Molecular Weight: 236.35. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E40063-T1: [Translated] MAGAZINE FOR A TOOL CHANGE DEVICE ON A SINGLE OR MULTI-SPINDLE DEEP DRILLING MACHINE.

1. A single-spindle or multi-spindle deep boring machine having a tool change device characterised in that the device (7) is formed by cylindrically arranged receiving tubes (8), wherein along a part of the length of the receiving tubes (8) the cross-section thereof is removed over an angle of somewhat more than 180 degrees, in such a way that for the purposes of receiving a deep boring tool (3, 3') perpendicularly to the axis of the receiving tube (8), wherein the inside diameter thereof is substantially equal to the diameter of the deep boring tool (3, 3'), an open half-shell is formed, from which the deep boring tool can be pushed into the remaining part in the axial direction of the receiving tube (8).
Association of circulating

Background
          Chlamydia pneumoniae antigens, nucleic acids, or intact organisms have been detected in human atheroma. However, the presence of antibody does not predict subsequent cardiovascular (CV) events. We performed a systematic review to determine whether the detection of C. pneumoniae DNA in peripheral blood mononuclear cells (PBMC) was associated with CV disease.
        
        
          Methods
          We sought studies of C. pneumoniae DNA detection in PBMC by polymerase chain reaction (PCR) among patients with CV disease or other clinical conditions. We pooled studies in which CV patients were compared with non-diseased controls. We analyzed differences between studies by meta-regression, to determine which epidemiological and technical characteristics were associated with higher prevalence.
        
        
          Results
          Eighteen relevant studies were identified. In nine CV studies with control subjects, the prevalence of circulating C. pneumoniae DNA was 252 of 1763 (14.3%) CV patients and 74 of 874 (8.5%) controls, for a pooled odds ratio of 2.03 (95% CI: 1.34, 3.08, P < 0.001). Prevalence was not adjusted for CV risk factors. Current smoking status, season, and age were associated with C. pneumoniae DNA detection. High prevalence (>40%) was found in patients with cardiac, vascular, chronic respiratory, or renal disease, and in blood donors. Substantial differences between studies were identified in methods of sampling, extraction, and PCR targets.
        
        
          Conclusions
          C. pneumoniae DNA detection was associated with CV disease in unadjusted case-control studies. However, adjustment for potentially confounding measures such as smoking or season, and standardization of laboratory methods, are needed to confirm this association.
Continuing HIV therapy in the ICU

The risks and benefits of stopping antiretroviral therapy in patients admitted to the ICU are largely unmeasured. In many cases therapy has to be stopped, as parenteral preparations are unavailable for all but one of the antiretroviral agents. Stopping treatment suddenly may be associated with increased risk of resistance because of the long half-life of some of the drugs, and also the risk of increased immunosuppression due to the viral load rebounding. Drugs given through the enteral route may be poorly absorbed, which again may lead to drug resistance. By inhibiting cytochrome P450 3A4 the drugs interfere with the metabolism of many other compounds routinely used in the ICU. Furthermore, the drugs themselves are occasionally associated with severe toxicity such as pancreatitis and lactic acidosis, which can have devastating consequences. Much active research in all of these areas is now needed.
Compound 526474: 7-Acetamidoflunitrazepam

Chemical compound data from PubChem database. IUPAC Name: N-[5-(2-fluorophenyl)-1-methyl-2-oxo-3H-1,4-benzodiazepin-7-yl]acetamide. Molecular Formula: C18H16FN3O2. Molecular Weight: 325.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
MD COVID-19 - Confirmed Deaths by Gender Distribution

<b>Note:</b> Starting April 27, 2023 updates change from daily to weekly.

<b>Summary</b>
The cumulative number of confirmed COVID-19 deaths among Maryland residents by gender: Female; Male; Unknown.

<b>Description</b>
The MD COVID-19 - Confirmed Deaths by Gender Distribution data layer is a collection of the statewide confirmed and probable COVID-19 related deaths that have been reported each day by the Vital Statistics Administration by gender. A death is classified as confirmed if the person had a laboratory-confirmed positive COVID-19 test result. Some data on deaths may be unavailable due to the time lag between the death, typically reported by a hospital or other facility, and the submission of the complete death certificate. Probable deaths are available from the MD COVID-19 - Probable Deaths by Gender Distribution data layer.

<b>Terms of Use</b>
The Spatial Data, and the information therein, (collectively the "Data") is provided "as is" without warranty of any kind, either expressed, implied, or statutory. The user assumes the entire risk as to quality and performance of the Data. No guarantee of accuracy is granted, nor is any responsibility for reliance thereon assumed. In no event shall the State of Maryland be liable for direct, indirect, incidental, consequential or special damages of any kind. The State of Maryland does not accept liability for any damages or misrepresentation caused by inaccuracies in the Data or as a result to changes to the Data, nor is there responsibility assumed to maintain the Data in any manner or form. The Data can be freely distributed as long as the metadata entry is not modified or deleted. Any data derived from the Data must acknowledge the State of Maryland in the metadata.
Texas (TX)

This report presents Texas\'s estimates for 25 measures of substance use and mental health based on the combined 2009 and 2010 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Resuts are provided for Texas for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.
Compound 529017: 5-Iodouracil, TMS

Chemical compound data from PubChem database. IUPAC Name: (5-iodo-2-trimethylsilyloxypyrimidin-4-yl)oxy-trimethylsilane. Molecular Formula: C10H19IN2O2Si2. Molecular Weight: 382.34. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 526563: 11,17-Dimethyltritriacontane

Chemical compound data from PubChem database. IUPAC Name: 11,17-dimethyltritriacontane. Molecular Formula: C35H72. Molecular Weight: 492.9. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
NNDSS - TABLE 1X. Meningococcal disease, Other serogroups to Meningococcal disease, Unknown serogroup

NNDSS - TABLE 1X. Meningococcal disease, Other serogroups to Meningococcal disease, Unknown serogroup - 2020. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.

Notice: Data from California published in week 29 for years 2019 and 2020 were incomplete when originally published on July 24, 2020. On August 4, 2020, incomplete case counts were replaced with a "U" indicating case counts are not available for specified time period. 

Note: 
This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. 

Footnotes:
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published.
NC: Not calculated — There is insufficient data available to support the calculation of this statistic.
Cum: Cumulative year-to-date counts.
Max: Maximum — Maximum case count during the previous 52 weeks.
* Case counts for reporting years 2019 and 2020 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf.
†Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).
Human disc cells in monolayer vs 3D culture: cell shape, division and matrix formation

Background
          The relationship between cell shape, proliferation, and extracellular matrix (ECM) production, important aspects of cell behavior, is examined in a little-studied cell type, the human annulus cell from the intervertebral disc, during monolayer vs three-dimensional (3D) culture.
        
        
          Results
          Three experimental studies showed that cells respond specifically to culture microenvironments by changes in cell shape, mitosis and ECM production: 1) Cell passages showed extensive immunohistochemical evidence of Type I and II collagens only in 3D culture. Chondroitin sulfate and keratan sulfate were abundant in both monolayer and 3D cultures. 2) Cells showed significantly greater proliferation in monolayer in the presence of platelet-derived growth factor compared to cells in 3D. 3) Cells on Matrigel™-coated monolayer substrates became rounded and formed nodular colonies, a finding absent during monolayer growth.
        
        
          Conclusions
          The cell's in vivo interactions with the ECM can regulate shape, gene expression and other cell functions. The shape of the annulus cell changes markedly during life: the young, healthy disc contains spindle shaped cells and abundant collagen. With aging and degeneration, many cells assume a strikingly different appearance, become rounded and are surrounded by unusual accumulations of ECM products. In vitro manipulation of disc cells provides an experimental window for testing how disc cells from given individuals respond when they are grown in environments which direct cells to have either spindle- or rounded-shapes. In vitro assessment of the response of such cells to platelet-derived growth factor and to Matrigel™ showed a continued influence of cell shape even in the presence of a growth factor stimulus. These findings contribute new information to the important issue of the influence of cell shape on cell behavior.
2015 CMHS Uniform Reporting System (URS) Table for Washington

2015 Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for Washington. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Compound 528284: 1-Heptene, 2,3-dimethyl

Chemical compound data from PubChem database. IUPAC Name: 2,3-dimethylhept-1-ene. Molecular Formula: C9H18. Molecular Weight: 126.24. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
SHIP Chlamydia Infection Rate 2008-2020

This is historical data. The update frequency has been set to "Static Data" and is here for historic value. Updated on 8/14/2024

Chlamydia infection rate - This indicator shows the rate of Chlamydia infections per 100,000 population. Chlamydia infections are usually without symptoms and go undiagnosed. They are associated with pelvic inflammatory disease, infertility, ectopic pregnancy and chronic pelvic pain. <a href ="https://health.maryland.gov/pophealth/Documents/SHIP/SHIP%20Lite%20Data%20Details/Chlamydia%20Infection%20Rate.pdf" > Link to Data Details </a>